Heliobacter Pylori Eradication Reduces Risk of Gastric Cancer for Over 10 Years
the Cancer Therapy Advisor take:
According to a recent study published in the Journal of Gastroenterology, eradicating the bacteria Heliobacter pylori in patients with peptic ulcer disease reduces the risk for developing gastric cancer for more than 10 years, but that gastric cancer can develop after that time period.
These results are part of a follow-up prospective cohort study in which patients were followed for as long as 17.4 years. Researchers previously reported that eradicating Heliobacter pylori in patients with peptic ulcer disease decreases the risk for developing stomach cancer to about 33% after an average follow-up of 3.4 years.
For the study, 1,222 patients with peptic ulcer disease who received over 1 year of follow-up after being treated for H. pylori received an annual endoscopy for an average of 9.9 years and for as long as 17.4 years.
Of the 1,222 patients, 1,030 were successfully cured of H. pylori and gastric cancer occurred in 21 of those patients. Of the 192 who were not successfully cured of H. pylori, 9 developed the disease. Statistical analyses show that the risk for developing gastric cancer was 0.21%/year and 0.45%/year in the eradication-success group and failure group, respectively.
Of those that developed gastric cancer in the eradication-success group, the longest interval between eradication and cancer occurrence was 14.5 years.
Eradicating Heliobacter pylori reduces risk for developing gastric cancer for more than 10 years.
The authors previously reported that eradication of Helicobacter pylori in the cohort of patients with peptic ulcer disease reduced their risk of developing gastric cancer to approximately one–third after a mean follow-up period of 3.4 years (up to 8.6 years) and now followed these patients for a longer period.
A prophylactic effect for gastric cancer persists for more than 10 years after H. pylori eradication therapy, but they should be aware that cancer can develop even after that interval.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations